Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LoBAG30 Diet in Patients on Metformin (LoBAG Diet)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00607867
Recruitment Status : Terminated (The funding ended before the study was completed.)
First Posted : February 6, 2008
Results First Posted : December 12, 2014
Last Update Posted : December 12, 2014
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development ( US Department of Veterans Affairs )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
We will determine the metabolic response to a Low Biologically Available Glucose Diet (LoBAG30) in subjects currently receiving the maximum dose of metformin as monotherapy in whom the glycohemoglobin is not at an acceptable level (>8.0%). Our hypothesis is that introduction of a LoBAG30 diet to subjects currently treated with a full therapeutic dose of metformin will improve blood glucose control in people who have not achieved an acceptable total glycohemoglobin on metformin alone.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Diet Other: LoBAG30 diet Other: Control Diet Not Applicable

Detailed Description:
Subjects will ingest a control diet (55% carbohydrate (CHO), 15% protein, 30% fat) or a LoBAG30 diet (30% CHO, 30% protein, 40% fat) in a parallel design with block randomization in pairs of two. Subjects will return to the study center twice each week while on the diets to have blood glucose, glycohemoglobin, lactate, weight and blood pressure measured, and to have urine assayed for urea and creatinine. At the beginning and end of the 5 week study period, the subjects will be admitted to the study center for 28 hours during which time blood will be drawn for 24 hour profiles of glucose, insulin, other hormones and several metabolites. For those subjects randomized to the LoBAG30 arm of the study, the control diet will be given during the first 24 hour study period; the assigned diet will be given at the end of the 5 week period.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Metabolic Response to a LoBAG30 Diet in Diabetic Patients on Metformin
Study Start Date : April 2008
Actual Primary Completion Date : January 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Metformin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm 1
A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
 Other: LoBAG30 diet
A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
Placebo Comparator: Arm 2
A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
 Other: Control Diet
A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in %Hemoglobin A1c at 5 Weeks From Baseline [ Time Frame: Baseline and 5 weeks after dietary intervention ]
    Hemoglobin A1c measured before and after 5 weeks on the diet

  2. Change in Total Glucose Area at 5 Weeks From Baseline [ Time Frame: Baseline and 5 weeks after dietary intervention ]
    The area response is measured using zero as baseline. The area is measured before dietary intervention, and following 5 weeks of dietary intervention.

  3. Change in Body Weight at 5 Weeks From Baseline [ Time Frame: baseline and 5 weeks after dietary intervention ]
    Subjects were to remain weight stable. We expected less than 2 pound weight change over 5 weeks. Weight was measured before dietary intervention, and after 5 weeks of dietary intervention.

  4. Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline [ Time Frame: baseline and 5 weeks after dietary intervention ]
    Overnight fasting glucose concentration was measured before dietary intervention and after 5 weeks of dietary intervention.


Secondary Outcome Measures :
  1. Microalbumin Excretion [ Time Frame: baseline and 5 weeks after dietary intervention ]
    change in urinary albumin excretion was measured before dietary intervention and after 5 weeks of dietary intervention

  2. Change in Fasting Triglycerides at 5 Weeks From Baseline [ Time Frame: baseline and 5 weeks after dietary intervention ]
    Overnight fasting triglycerides concentration was measured before dietary intervention and after 5 weeks of dietary intervention


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • People with type 2 diabetes mellitus who currently are receiving the maximal dose of metformin monotherapy (2500 mg/day).
  • These subjects will have had a stable glycohemoglobin (tGHb) in an unacceptably high range (8-11%) for at least 4 months prior to beginning the study.
  • Subjects with tGHB > 11% (HbA1c > 10%) will not be recruited into the study.

Exclusion Criteria:

  • Hematological abnormalities
  • liver disease
  • kidney disease
  • macroalbuminuria (>300 mg albumin/24 hours)
  • untreated thyroid disease
  • congestive heart failure
  • angina
  • life-threatening malignancies
  • proliferative retinopathy
  • severe diabetic neuropathy
  • peripheral vascular disease
  • serious psychological disorders
  • a body mass index > 35

  • and a fasting triglyceride of >400 mg/dl.

    • Subjects taking slow-release metformin will not be studied.
    • Subjects taking medications other than metformin, known to affect fuel metabolism such as:
  • insulin
  • the sulfonylureas
  • glucagon-like peptide 1 (GLP-1) analogs and metabolic inhibitors
  • pramlintide
  • prednisone and similar steroids
  • thyroid hormone
  • antipsychotic medications
  • thiazide diuretics
  • medroxyprogesterone

  • high dose aspirin, also will be excluded.

    • If concentrations of serum folate, B12 or iron are low, the subject will be excluded from the study until corrected, i.e. until normal concentrations are recorded.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00607867


Locations
Layout table for location information
United States, Minnesota
VA Medical Center, Minneapolis
Minneapolis, Minnesota, United States, 55417
Sponsors and Collaborators
US Department of Veterans Affairs
Investigators
Layout table for investigator information
Principal Investigator: Mary Gannon, PhD Minneapolis Veterans Affairs Medical Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: US Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00607867    
Other Study ID Numbers: CLIN-010-07F
First Posted: February 6, 2008    Key Record Dates
Results First Posted: December 12, 2014
Last Update Posted: December 12, 2014
Last Verified: December 2014
Keywords provided by VA Office of Research and Development ( US Department of Veterans Affairs ):
Diabetes Mellitus (type 2)
Diet
Glycohemoglobin
Lipids
 Kidney Function
Glycemic Index
Dietary Protein
Dietary Carbohydrate
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases